Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 17 amino acid peptide from near the center of human IFN-b.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||5 ug/ml|
|Western Blot (WB)||5 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
A suggested positive control is A-20 cell lysate.
PA5-20390 can be used with blocking peptide PEP-0507.
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by “Natural IFN-producing cells" (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
PA5-20390 was used in immunohistochemistry to analyze the function of STING in activating tumor endothelial cells and antitumor immunity
|Demaria O,De Gassart A,Coso S,Gestermann N,Di Domizio J,Flatz L,Gaide O,Michielin O,Hwu P,Petrova TV,Martinon F,Modlin RL,Speiser DE,Gilliet M||Proceedings of the National Academy of Sciences of the United States of America (112:15408)||2015|
Fibroblast interferon; IFN-beta; Interferon beta; interferon, beta 1, fibroblast; interferon-beta; RP11-113D19.1, IFB, IFF, IFNB
IFB; IFF; IFN-beta; IFNB; IFNB1